15592-37-7
Chemical Structure
Glucoerucin potassium
- CAS No.: 15592-37-7
- Formula:C12H22KNO9S3
- Molecular Weight:459.60
IUPAC Name: potassium ((Z)-5-(methylthio)-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)pentylidene)amino sulfate
InChIKey: CFTVNYXGWYKWFH-SNPNTKKDSA-M
SMILES: CSCCCC/C(S[C@@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO)=N/OS(=O)(O[K])=O
Biological Activity: Glucoerucin potassium is an orally active PTP1B non-competitive allosteric inhibitor (IC50 = 6.07 μM) and H2S donor that can be isolated and extracted from Eruca sativa. Glucoerucin potassium upregulates the Nrf2 pathway and promotes irisin/UCP1-mediated adipose tissue browning through conversion to erucin or acting as a sustained-release H2S donor, thereby regulating metabolic and cardiovascular functions. Glucoerucin potassium also exerts anticancer effects by upregulating epoxide hydrolase and through non-competitive allosteric inhibition of PTP1B. Glucoerucin potassium can be used in research on obesity, cancer, type 2 diabetes, and cardiovascular and cerebrovascular diseases[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glucoerucin potassium | 99.73% | Glucoerucin potassium is an orally active PTP1B non-competitive allosteric inhibitor (IC50 = 6.07 μM) and H2S donor that can be isolated and extracted from Eruca sativa. Glucoerucin potassium upregulates the Nrf2 pathway and promotes irisin/UCP1-mediated adipose tissue browning through conversion to erucin or acting as a sustained-release H2S donor, thereby regulating metabolic and cardiovascular functions. Glucoerucin potassium also exerts anticancer effects by upregulating epoxide hydrolase and through non-competitive allosteric inhibition of PTP1B. Glucoerucin potassium can be used in research on obesity, cancer, type 2 diabetes, and cardiovascular and cerebrovascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Piragine E, et al. Eruca sativa Mill. seed extract promotes anti-obesity and hypoglycemic effects in mice fed with a high-fat diet. Phytotherapy research : PTR. 2021 Apr;35(4):1983-1990.
- [2]. Citi V, et al. Anticancer properties of erucin, an H2S‐releasing isothiocyanate, on human pancreatic adenocarcinoma cells (AsPC‐1). Phytotherapy Research. 2019 Mar;33(3):845-55. [Content Brief]
- [3]. Abdull Razis AF, et al. Up-regulation of cytochrome P450 and phase II enzyme systems in rat precision-cut rat lung slices by the intact glucosinolates, glucoraphanin and glucoerucin. Lung cancer (Amsterdam, Netherlands). 2011 Mar;71(3):298-305.
- [4]. Nastruzzi C, et al. In vitro cytotoxic activity of some glucosinolate-derived products generated by myrosinase hydrolysis. Journal of Agricultural and Food Chemistry. 1996 Apr 18;44(4):1014-21.
- [5]. Abdull Razis AF, et al. Induction of epoxide hydrolase and glucuronosyl transferase by isothiocyanates and intact glucosinolates in precision-cut rat liver slices: importance of side-chain substituent and chirality. Archives of toxicology. 2011 Aug;85(8):919-27.
- [6]. Flori L, et al. Glucoerucin, Glucosinolate From Brassicaceae Vegetables, Improves the Metabolic Profile in a Murine Model of Diet-Induced Obesity. Phytotherapy research : PTR. 2026 Jul;40(7):4556-4570.
- [7]. Testai L, et al. Cardiovascular benefits of Eruca sativa mill. Defatted seed meal extract: Potential role of hydrogen sulfide. Phytotherapy research : PTR. 2022 Jun;36(6):2616-2627.
- [8]. Barillari J, et al. Direct antioxidant activity of purified glucoerucin, the dietary secondary metabolite contained in rocket (Eruca sativa Mill.) seeds and sprouts. Journal of agricultural and food chemistry. 2005 Apr 06;53(7):2475-82.
- [9]. Ahmed NA, et al. Watercress-derived glucosinolates as potential allosteric PTP1B inhibitors: a dual in silico and in vitro study on insulin signaling modulation. BMC chemistry. 2025 Jun 19;19(1):169.
